Previous 10 | Next 10 |
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2 nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients Acromegaly patients were exposed to M ycapssa...
The following slide deck was published by Amryt Pharma plc in conjunction with this event. For further details see: Amryt Pharma (AMYT) Investor Presentation - Slideshow
Amryt Supports World Lipodystrophy Day - March 31, 2022 DUBLIN, Ireland, and Boston MA, March 31, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is p...
Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB Late-breaking oral presentation at the American Academy of Dermatology Annual meeting 2022 Body surface area percentage of partial thickness wounds reduced from 12.1% to ...
The following slide deck was published by Amryt Pharma plc in conjunction with their 2021 Q4 earnings call. For further details see: Amryt Pharma plc 2021 Q4 - Results - Earnings Call Presentation
Amryt Pharma (AMYT) Q4 2021 Earnings Conference Call March 9, 2022, 8:30 AM ET Company Participants Dr. Joe Wiley – Chief Executive Officer Rory Nealon – Chief Financial Officer and Chief Operations Officer Sheila Frame – President, Americas Mark Sumeray – Chief Me...
Amryt Pharma press release (NASDAQ:AMYT): Q4 GAAP EPS of $0.07 beats by $0.12. Revenue of $54.8M (+28.9% Y/Y) misses by $1.8M. Guidance: The company is issuing revenue guidance for FY 2022 in the range of $260M - $270M vs consensus of $292.48M which represents growth of 17% to 21% on FY ...
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves stock repurchase program of up to $30M 8 th consecutive quar...
Amryt (NASDAQ:AMYT) said it successfully completed a phase 1 study study for Mycapssa (oral octreotide) and the data will support a planned phase 3 study of the drug to treat patients with carcinoid symptoms due to Neuroendocrine Tumors (NET). The company said its TPE platform enables the ora...
Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules ) Data support s a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumor s (NET) Global ...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...